<DOC>
	<DOCNO>NCT00887965</DOCNO>
	<brief_summary>To characterize effect discontinuation denosumab therapy variables bone histology postmenopausal woman low bone mass osteoporosis . Patients receive denosumab complete study 20050179 ( NCT00293813 ) , complete study 20050141 ( NCT00330460 ) , complete study 20060237 ( NCT00515463 ) , complete study 20030216 ( NCT00089791 ) enroll study 20060289 ( NCT00523341 ) include study . Patients participate off-treatment imaging study 20080747 ( NCT00890981 ) also eligible .</brief_summary>
	<brief_title>A Transiliac Crest Bone Histology Histomorphometry Study Postmenopausal Women With Low Bone Mass Osteoporosis Previously Treated With Denosumab</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>Ambulatory postmenopausal woman Received denosumab complete study 20050179 ( NCT00293813 ) , complete study 20050141 ( NCT00330460 ) , complete study 20060237 ( NCT00515463 ) , complete study 20030216 ( NCT00089791 ) enroll study 20060289 ( NCT00523341 ) . Patients participate offtreatment image study 20080747 ( NCT00890981 ) also eligible . Completed participation eligible study ≥ 12 ≤ 36 month prior screen Provide sign informed consent Did receive denosumab study 20050141 , 20060237 , 20030216 , 20050179 . Discontinued investigational product end study visit study 20050141 , 20060237 , 20030216 , 20050179 . Received &gt; 1 month osteoporosis treatment since complete study 20050141 , 20060237 , 20030216 , 20050179 . Received zoledronic acid time end study participation parent study 20050141 , 20050179 , 20030216 , 20060237 . Newly diagnose follow condition intervene period since complete study 20050141 , 20060237 , 20030216 , 20050179 : Hyperthyroidism ( stable antithyroid therapy postablation allow , Thyroid Stimulating Hormone within normal range ) Hypothyroidism ( stable thyroid replacement therapy allow , Thyroid Stimulating Hormone within normal range ) Hyper hypoparathyroidism Osteomalacia Paget 's disease bone Other bone disease affect bone metabolism ( eg , osteopetrosis , osteogenesis imperfecta ) Malignancy within last 5 year ( except cervical carcinoma situ basal cell carcinoma ) . Selfreported alcohol drug abuse within previous 12 month . Permanently nonambulatory subject ( use assistive device eg cane , walker permit ) . Has know suspect sensitivity contraindication tetracycline derivative . Received investigational product denosumab . Current use follow osteoporosis agent : bisphosphonates , calcitonin , fluoride , parathyroid hormone analogue , selective estrogen receptor modulators , systemic oral transdermal estrogen ( except vaginal preparation estrogen cream acceptable ) , strontium tibolone . Has undergone bilateral transiliac crest bone biopsy past . Current use medication , opinion investigator , discontinue may compromise safety subject undergo bone biopsy procedure ( eg , aspirin , warfarin , highdose heparin ) . Current use systemic glucocorticoid therapy ( topical nasal steroid permit ) . Evidence coagulopathy opinion investigator , may compromise patient safety subject bone biopsy procedure . Any disorder , opinion investigator , may compromise ability participant give write informed consent and/or comply study procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Low Bone Mass</keyword>
	<keyword>Low Bone Mineral Density</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal Osteoporosis</keyword>
	<keyword>Bone Biopsy</keyword>
	<keyword>Transiliac Crest Bone Histology</keyword>
	<keyword>Histomorphometry</keyword>
</DOC>